Daily Cardiology Research Analysis
Three studies stand out today: a nationwide time-series plus animal study links ambient polycyclic aromatic hydrocarbons to higher cardiovascular hospitalizations with mechanistic support; a massive real-world analysis shows earlier initiation and better adherence to SGLT2 inhibitors markedly improve survival in heart failure with diabetes; and a polygenic risk score helps stratify stroke/systemic embolism risk in atrial fibrillation patients with low–intermediate clinical risk.
Summary
Three studies stand out today: a nationwide time-series plus animal study links ambient polycyclic aromatic hydrocarbons to higher cardiovascular hospitalizations with mechanistic support; a massive real-world analysis shows earlier initiation and better adherence to SGLT2 inhibitors markedly improve survival in heart failure with diabetes; and a polygenic risk score helps stratify stroke/systemic embolism risk in atrial fibrillation patients with low–intermediate clinical risk.
Research Themes
- Environmental cardiology and population health risk
- Therapeutic timing and adherence in heart failure management
- Genomics-driven precision risk stratification in atrial fibrillation
Selected Articles
1. Ambient polycyclic aromatic hydrocarbons and cardiovascular disease in China.
Across 184 Chinese cities (2014–2017), each interquartile range increase in ambient PAHs was associated with higher daily hospitalizations for cardiovascular disease, ischemic heart disease, and ischemic stroke. Parallel mouse experiments confirmed PAH-induced cardiac injury with transcriptomic/proteomic signatures, providing mechanistic support for the epidemiologic associations.
Impact: This integrative population–mechanistic study identifies PAHs as a modifiable environmental cardiotoxicant with immediate public health relevance, expanding beyond PM2.5-centric risk frameworks.
Clinical Implications: Clinicians should consider air pollution (including PAHs) as a cardiovascular risk modifier, counsel high-risk patients on exposure reduction, and support policies targeting combustion-derived pollutants.
Key Findings
- Each IQR increase in ambient PAHs (lag 0–7 days) associated with +5.18% cardiovascular hospitalizations.
- +5.72% for ischemic heart disease and +6.08% for ischemic stroke per IQR increase in PAHs.
- Associations persisted after adjusting for co-pollutants (e.g., particulate matter).
- Mouse PAH exposure induced cardiac injury with transcriptomic and proteomic pathway changes.
Methodological Strengths
- Nationwide multi-city time-series with meta-analysis across 184 cities, large population coverage.
- Triangulation with controlled animal experiments and multi-omics for mechanistic support.
Limitations
- City-level exposure metrics may introduce exposure misclassification and ecological bias.
- Residual confounding by unmeasured factors cannot be fully excluded; clinical outcomes were hospitalizations, not incident disease.
Future Directions: Personal-level exposure assessment, interventional policies targeting PAHs, and studies linking exposure reductions to cardiovascular outcomes are warranted.
Polycyclic aromatic hydrocarbons (PAHs) are a prominent category of ambient air pollutants worldwide, but our understanding of their potential health effects at ambient concentrations is severely limited. Our goal was to investigate the relation between ambient PAHs and daily hospitalizations for cardiovascular disease and explore its potential mechanism. This research included both observational and experimental studies. For population-based study, we collected data on daily hospitalizations for cardiovascular events in 184 major Chinese cities, which cover a population of 280 million individuals, for period of 2014-2017. We utilized a time-series quasi-Poisson regression model to assess the city-specific relations between PAHs and hospitalizations, and then employed a random-effects meta-analysis to aggregate the effect estimates across the cities. We also employed meta-regression models and stratified analyses to explore possible effect modifiers. For animal study, mice were exposed to varying doses of PAHs via tracheal instillation to evaluate the cardiac damage induced by PAHs. Potential mechanisms were elucidated through transcriptomic and proteomic sequencing. On the national scale, each interquartile range (IQR) increase in PAHs concentrations at 0-7 days was related to a 5.18 % (3.27 %-7.12 %) increase in hospital admissions for cardiovascular disease, 5.72 % (3.83 %-7.65 %) for ischemic heart disease, and 6.08 % (3.37 %-8.87 %) for ischemic stroke. The cardiovascular impacts of PAHs remained even after controlling for PM
2. Timing and Adherence Matter for Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure.
In 1,229,833 patients with heart failure and diabetes, SGLT2 inhibitors were associated with lower all-cause mortality, with the greatest benefit when initiated before the index HF diagnosis and maintained beyond a median 417 days. After HF diagnosis, every >10% drop in proportion of days covered correlated with a 59% increase in all-cause death.
Impact: This analysis provides compelling real-world evidence that early initiation and sustained adherence to SGLT2 inhibitors can maximize survival gains in HF with diabetes, informing implementation strategies.
Clinical Implications: Prioritize early SGLT2 inhibitor initiation in eligible diabetes patients, even before HF diagnosis, and implement adherence monitoring/interventions (e.g., refill synchronization, digital reminders) to sustain benefits.
Key Findings
- Median pre-HF SGLT2i exposure was 417 days; exposure above this threshold conferred the best prognosis.
- Initiation before index HF diagnosis yielded the greatest survival benefit.
- After HF diagnosis, >10% decrease in proportion of days covered was associated with a 59% increase in all-cause mortality (HR 1.21–2.09).
Methodological Strengths
- Exceptionally large nationwide cohort enabling precise estimates and subgroup analyses.
- Clear operationalization of timing and adherence using pre-diagnosis exposure duration and proportion of days covered.
Limitations
- Observational design with potential residual confounding and channeling bias.
- Adherence (PDC) reflects dispensing, not ingestion; medication indications and dose changes may vary.
Future Directions: Prospective adherence-optimization trials and health-system interventions to initiate SGLT2i earlier and maintain high PDC, including digital adherence technologies.
BACKGROUND: It is imperative to maintain the use of sodium-glucose cotransporter-2 inhibitors (SGLT-2is) in patients with diabetes both after the index diagnosis of heart failure (HF) and even prior to the index diagnosis of HF. We aimed to investigate whether timing of SGLT-2 is before the index diagnosis of HF, and second, adherence to SGLT-2is in the form of the proportion of days covered metric matter in patients with HF and diabetes. METHODS AND RESULTS: All-cause death up to 7 years were evaluated in HF with diabetes from the subgroup analysis of TRends-HF (TRends in Heart Failure in Türkiye). Patients with HF and diabetes, who were prescribed an SGLT-2i either before or after the index diagnosis of HF were identified, categorized according to duration of exposure before the index HF diagnosis and according to proportion of days covered after the index diagnosis of HF, and compared with nonusers. There were 1 1229 833 patients with HF and diabetes in the cohort. A total of 247 87 were on an SGLT-2i and had available timing data, and 14.06% had SGLT-2i on board before the index HF diagnosis. Median duration of SGLT-2i exposure before the index HF diagnosis was 417 days. Prognosis was the best among patients with diabetes who were prescribed an SGLT-2i before the index diagnosis of HF with an exposure more than median duration. Of note, among patients who were prescribed an SGLT-2i after the index HF diagnosis; there was a numerically graded increase in all-cause mortality rate such that a >10% decrease in SGLT-2i proportion of days covered was associated with a 59% increase in all-cause death (hazard ratio, 1.21-2.09). CONCLUSIONS: Regardless of time or adherence, SGLT-2is offer a remarkable all-cause death benefit to patients with HF and diabetes. SGLT-2is' all-cause death benefit for patients with HF and diabetes was greatest when it was prescribed before the HF index diagnosis. Poor adherence to SGLT-2is was associated with worsening survival in patients with HF and diabetes following the diagnosis of index HF.
3. Polygenic Risk and Cardiovascular Event Risk in Patients With Atrial Fibrillation With Low to Intermediate Stroke Risk.
Among 9,597 oral anticoagulation-naive AF patients with low–intermediate CHA2DS2-VASc risk, higher AF polygenic risk was associated with increased stroke/systemic embolism. These findings support integrating genetic risk with clinical scores to refine decision-making.
Impact: Demonstrates the additive value of polygenic risk in AF patients who present the greatest clinical equipoise for anticoagulation, advancing precision prevention.
Clinical Implications: Genetic risk profiling may help identify low–intermediate risk AF patients who could benefit from closer monitoring or earlier anticoagulation; prospective validation and integration with CHA2DS2-VASc are needed.
Key Findings
- Polygenic risk was positively associated with stroke/systemic embolism among AF patients with low–intermediate clinical risk.
- Cohort included 9,597 oral anticoagulation–naive AF patients, minimizing treatment confounding.
- Findings support combining genetic and clinical risk for refined stratification.
Methodological Strengths
- Restriction to oral anticoagulation–naive patients reduces confounding by treatment.
- Focus on low–intermediate risk group addresses a key clinical decision gap.
Limitations
- Abstract lacks detailed hazard ratios and covariate adjustments; full methodological details are not provided here.
- Generalizability across ancestries and clinical settings requires validation.
Future Directions: Prospective trials to test PRS-guided anticoagulation strategies and multi-ancestry validation to ensure equity and calibration.
BACKGROUND: The clinical utility of the polygenic risk score in predicting cardiovascular events in patients with atrial fibrillation (AF) has not yet been established. This study aimed to determine whether the polygenic risk score for AF might be useful in the risk stratification of AF-related cardiovascular events. METHODS AND RESULTS: This study included 9597 oral anticoagulation-naive patients with AF with a CHA CONCLUSIONS: In patients with AF with low-intermediate stroke risk, genetic risk for AF is associated with increased risk of stroke or systemic embolism.